Hunan Dinuo Pharmaceutical Co. Ltd.

Primary objective: Orlistat capsules (specification: 60 mg) of Hunan Dino Pharmaceutical Co., Ltd. were used as the test preparation, and orlistat capsules (specification: 60 mg, trade name: Alli®) of GlaxoSmithKline Consumer Healthcare were used as the reference preparation. The pharmacodynamic differences between the two orlistat capsules were investigated. The bioequivalence of the two preparations was evaluated. Secondary objective: To observe the safety of repeated use of orlistat capsules in healthy study participants.

To investigate the pharmacokinetic characteristics of vonoprazan fumarate tablets (20 mg) developed and produced by Hunan Dino Pharmaceutical Co., Ltd. after a single oral administration after a meal; to compare the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations with vonoprazan fumarate tablets (Walker®, 20 mg) produced by Takeda Pharmaceutical Company Limited as the reference preparation, and to evaluate the bioequivalence of the two preparations in humans.

The aim was to study the pharmacokinetic characteristics of a single fasting oral dose of vonoprazan fumarate tablets (20 mg) developed and produced by Hunan Dino Pharmaceutical Co., Ltd.; using vonoprazan fumarate tablets (Walker®, 20 mg) produced by Takeda Pharmaceutical Company Limited as the reference preparation, to compare the pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two preparations, and to evaluate the bioequivalence of the two preparations in humans.